Seed Round — Open Now · 2026
Egypt's First AI
Health Insurance Platform
Is Raising $1M.
SAFE Note · 18–36 month uncontested regulatory window · FRA-licensed · 70% gross margin · Zero incumbent competitor. One TPA partnership covers 1.2M insured lives across 18 insurers — before we sign a single insurer directly.
$1M
Seed Round Ask
70%
Gross Margin
20–30×
LTV / CAC Ratio
18 mo
Runway Target
🔒 This page is for accredited investors and institutional partners. Information is confidential and subject to NDA.
Why iRonic Health
Three Reasons This Investment Works
Market timing, regulatory tailwind, and a capital-efficient model that reaches breakeven on $1M — not $10M.
⏰
The 18–36 Month Window
The FRA licensed 6 TPAs in April 2026. This opens a channel that didn't exist before — and creates an 18–36 month window before incumbents realize what happened and mobilize. No Egyptian insurer deploys AI fraud detection at scale today. First-mover locks the market.
FRA Decision 229/2025 · April 2026 · 6 TPAs licensed
🎯
One Deal = 18 Insurers
GlobeMed Egypt manages 1.2M insured lives across 18 insurance companies. A single TPA partnership replaces 18 separate insurer sales cycles — each of which takes 6–12 months. Our TPA-first GTM compresses 5 years of sales work into 3–6 months. No competitor can replicate this without a pre-existing relationship.
GlobeMed Egypt · 1.2M lives · 18 insurers · Strategic target
💰
Capital-Efficient Path
Contingent pricing means we earn 25% of validated fraud savings — zero upfront cost for the insurer, zero financial risk in the pilot. This removes the #1 sales objection and means we generate revenue from Month 5, reach $475K ARR (Base Case) by Month 12, and approach breakeven by Month 18 — all on $1M of seed capital.
$1M seed → $475K ARR Month 12 (Base) → Series A ready
Market Sizing
A $373M Market
With Zero AI Competition
Egypt's private health insurance market is growing 15% YoY with 6–8M insured lives and rising loss ratios. Not a single insurer deploys AI fraud detection at scale.
TAM
$373M
Egypt private health GWP 2024 · growing +15% YoY · FRA / Statista
SAM
$80–150M
Top 10 insurers/TPAs with 500K+ members · $80–150M addressable
SOM · 3-Year Target
$18M
3–4 anchor clients · 1.5–2.5M lives · $4–6 PMPM + fraud recovery share
Market Signals
📈
Loss Ratios at Record Highs
Egyptian private insurer loss ratios at 70–85% and rising 50–60% YoY. Every CFO is looking for a solution now — not in 2 years.
⚖️
FRA Licensed 6 TPAs (April 2026)
First regulatory opening for TPA-based AI fraud detection. A compliance path that didn't exist before April 2026.
🏛️
Unified Insurance Law 155/2024
Opens self-funded corporate schemes as a new insurance channel — an entirely new buyer segment for iRonic Health.
🧪
Documented Fraud Problem
2–10% fraud / abuse loss rate documented by RGA Middle East across 37 Egyptian insurers. At $373M GWP, that's $7–37M lost annually — before our solution exists.
🌍
MENA Expansion Ready (Y3)
KSA NPHIES certification in roadmap. Saudi market: 5–10M insured lives at $2–5 PMPM = $12–50M additional ARR potential.
🏥
GlobeMed Egypt Partnership
TPA partner manages 1.2M insured lives across 18 insurers. One signed agreement = immediate multi-insurer deployment path.
3-Year Forecast
From $475K to $7.35M ARR
In 36 Months
Anchored by PMPM platform fees and a 15% fraud recovery share. 70% gross margin throughout. Breakeven on $1M of capital by Month 18.
| Metric | Year 1 | Year 2 | Year 3 |
|---|---|---|---|
| Anchor Customers | 1–2 | 3–4 | 6–8 |
| Total Lives on Platform | 375K | 1.4M | 4.2M |
| Platform PMPM Revenue | $225K | $1.05M | $3.78M |
| Recovery Share (15%) | $250K | $1.05M | $2.52M |
| Pharmacy Module | — | $350K | $1.05M |
| Total ARR | $475K | $2.45M | $7.35M |
| Gross Margin | 70% | 70% | 70% |
| EBITDA | ($975K) | ($485K) | +$1.95M |
| Annual Burn | ~$1.5M | ~$800K | Positive |
Series A Path
Series A Target
$2–3M
Month 12–15 · Upon $475K ARR milestone (Base Case) · 2–3 anchor customers
Series A use of funds
Sales team expansion (10+ enterprise reps) · Product: pharmacy audit, spend optimization · Regional hiring (KSA / UAE expansion)
Acquisition scenarios (Y2–Y3)
Tier-1 insurers (Misr, AXA, Bupa) seeking AI capability → $20–30M · Global health-tech platforms seeking Egypt entry → $30–50M · Regional consolidators (GIG, Allianz) → $15–25M
Breakeven Analysis
Month 18 breakeven with disciplined spending · $1M seed provides full 18-month runway · Contingent pricing model generates revenue from Month 5 without upfront capital outlay
Unit Economics
Best-in-Class Metrics
From Month One
Contingent pricing means CAC payback starts immediately. A 20–30× LTV/CAC ratio — when the benchmark for top-tier SaaS is 3× — is not a typo.
Customer Acquisition Cost (CAC)
$30–50K
Per insurer or TPA · Includes sales cycles, product setup, and onboarding. Enterprise SaaS benchmark: $50–100K.
↓ Below benchmark
LTV (3-Year, Per Customer)
$500K–$1.5M
PMPM recurring + 15% fraud recovery share over 3 years. Large TPA (1.2M lives) at higher end.
↑↑ High LTV
LTV / CAC Ratio
20–30×
Gold standard SaaS benchmark is 3×. We're 7–10× above it — driven by high LTV and low acquisition cost via TPA channel.
🏆 Gold standard: 3× — we're at 20–30×
Gross Margin
70%
COGS = 30% (cloud infra + AI model maintenance + processing). Best-in-class SaaS target is 70%+.
✓ Meets best-in-class target
CAC Payback Period
4–6 mo
Contingent model: we earn 25% of savings immediately — cost recovery starts Month 1–2. Full payback by Month 4–6.
↓↓ Typical SaaS: 12–18 months
Average Contract Value (ACV)
$225K+
Y1 per anchor insurer. Scales to $500K–$1M+ as lives increase and modules expand (pharmacy, dynamic premiums, routing).
Expands 2–4× by Y3
Capital Allocation
How $1M
Gets Deployed
Every dollar mapped to a specific output — no vague "general expenses." GTM-heavy allocation because the product is largely designed; we need to sell and prove it.
Seed Round Size
$1M
SAFE Note · Convertible Note
Range: USD $800K – $1.2M
Range: USD $800K – $1.2M
Instrument: SAFE Note or Simple Convertible Note
Target investors: Healthcare / Fintech angels · MENA-focused VCs (Flat6Labs, Sayt VC) · Impact VCs · Insurer CVCs · Cairo Angels
Pro-rata rights: Available for investors $100K+
Board observer seat: Available for lead investor
Target investors: Healthcare / Fintech angels · MENA-focused VCs (Flat6Labs, Sayt VC) · Impact VCs · Insurer CVCs · Cairo Angels
Pro-rata rights: Available for investors $100K+
Board observer seat: Available for lead investor
✓ 18-month runway · Breakeven Month 18
Seed → Series A
12-Month Milestone
Roadmap
Each milestone unlocks the next. Clear, measurable, investor-reportable.
M2
Month 2
MVP Live
AI fraud detection deployed · FRA-compliant API · Dashboard live
Technical PoC
M3
Month 3
First Pilot Signed
50K–100K lives · Contingent pricing · GlobeMed or mid-tier insurer
Commercial Validation
M6
Month 6
ROI Documented
>10% fraud savings validated · Reference case ready · Revenue begins
Anchor Reference
M9
Month 9
First PMPM Contract
300K+ lives · Recurring ARR begins · Full platform deployed
Recurring Revenue
M12
Month 12
$475K ARR (Base)
1–2 anchor clients · Series A criteria met · MENA expansion prep
Series A Ready
Defensibility
Why Competitors
Can't Catch Up
Five compounding moats — any one is hard to replicate. Together they create a durable competitive position for 3–5 years.
🧠
Egypt-Native AI Models
Trained on Egypt-specific fraud archetypes, ICD/CPT codes, local pharmacy patterns, and FRA-defined fraud categories. A competitor importing a global model misses 60–70% of Egypt's specific fraud patterns — Unictam counterfeits, Egyptian prescription forgery methods, local ICU billing games.
25–40 archetypes · No global model has these
🏛️
FRA First-Mover Advantage
We're building the regulatory precedent — not just complying with it. By the time competitors understand the FRA's TPA licensing framework and navigate the CMO oversight requirement, we'll have 12–18 months of live data, validated accuracy, and an insurer reference case that no new entrant can replicate.
FRA Decision 229/2025 · 18–36 month window
🔗
TPA-Native Distribution
GlobeMed Egypt covers 1.2M lives across 18 insurers. Our competitors must sign 18 separate insurer deals — each 6–12 months. We compress that into one TPA partnership. This distribution moat is structural: TPAs have contractual exclusivity windows that prevent insurers from deploying competing solutions without TPA consent.
1 TPA deal = 18 insurer deals · 3–6 month vs. 5+ years
💼
Contingent Pricing Lock-In
Once an insurer is in our pilot — earning fraud recoveries with zero upfront cost — switching to a competitor means paying a platform fee upfront, risking performance uncertainty, and losing the CMO governance layer they've come to rely on for FRA compliance. Switching cost = high. Inertia = our friend.
Zero-risk entry · High switching cost after pilot
🩺
CMO Clinical Governance Layer
Every AI decision has a licensed Egyptian Medical Syndicate CMO as oversight. This is not optional — it's FRA-mandated for high-severity claim denials. Building and training a CMO oversight process takes 6–12 months for any new entrant, and requires a CMO willing to stake their license on the AI's accuracy.
Egyptian Medical Syndicate CMO · FRA-mandated
📊
Data Network Effect
Every claim processed makes our fraud models smarter. At 375K lives in Year 1 growing to 4.2M in Year 3, we're accumulating Egypt's largest private claims dataset. A new entrant starting in Year 2 will be training their models on 3–4 years less data — with no benchmark against which to validate.
375K → 4.2M lives · Largest Egypt claims dataset
Transparent Risk Assessment
Known Risks &
How We Address Them
We don't hide risk. We've mapped every material risk, its probability, and our specific mitigation. This is the same analysis we share with our legal and compliance team.
| Risk | Level | Mitigation |
|---|---|---|
| Sales cycle longer than 3 months Insurer procurement takes 6–12 months in Egypt |
Medium |
Contingent pricing eliminates budget approval barrier · CEO has existing insurer relationships · GlobeMed TPA route bypasses insurer procurement entirely |
| AI false positive rate too high Incorrectly flagging valid claims damages insurer trust |
Low–Med |
Conservative threshold settings in pilot phase · CMO reviews all high-value flags · False positive rate monitored monthly · Insurers only see clean evidence before rejection |
| FRA regulatory change FRA modifies TPA licensing or AI decision rules |
Low |
Proactive FRA engagement in progress · CMO governance layer built for regulatory flexibility · PDPL and FRA compliance embedded in product architecture from day 1 |
| Technical execution risk MVP delayed beyond Month 2 |
Low |
MVP scope locked to fraud detection only (not full platform) · 2–3 FTE engineers · Existing fraud frameworks adapted, not built from zero · Yodawy integration explored as fallback pharmacy data source |
| Incumbent competition emerges Global insurer-tech or pharma company enters Egypt |
Low |
Egypt-native AI models take 12–18 months to build · FRA regulatory precedent takes 6–12 months to navigate · TPA partnerships are exclusive during pilot · Data moat grows monthly |
Seed Round Open · 2026
Join the $1M Round
Request the full investor deck, financial model, and data room access. We respond to all qualified investors within 24 hours.
Request Investor Materials
Full deck · 3-year financial model · Data room access · Available to qualified investors
🔒 Confidential. NDA available on request. PDPL 151/2020 compliant data handling.
✅
Request Received — Thank You
We'll send the investor deck and data room access within 24 hours. Check your inbox.